Overview

68Ga-NI-FAPI PET/CT: First-in-human Study

Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University